Cel Sci Corporation (CVM)

[rwa3848]

InVentiv, as a corporate entity after the merger, exists only for the sake of its ongoing litigation. Is the InVentiv v Navigator's case really a contest to decide how & when arbitration costs are written off (looks better for INC research if cost does not appear until 2018, I suspect) (while Navigators, as an established entity since 1974 & with a market cap of 1.6 billion & quarterly revenues of 300 million, would likely prefer to have the loss mitigate fy2017 taxes )....other questions to ask are 1) what is the coverage cap of PharmaNet's insurance policy & 2) what is the probability that an arbitration award to Cel-Sci will exceed coverage limits *thus entailing PharmaNet/ Inventiv/INC research must make up in payment***
...
I expect Cel-Sci to gain more than 50 million from arbitration with only a very slight chance that the award maxes at 100 million